Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT plus camrelizumab for oligometastatic esophageal squamous cell carcinoma (Phase II)
ChiCTR2200057417Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Objective response rate. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2200057417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057417.